Primary dural lymphomas: Clinical presentation, management, and outcome
- PMID: 32176324
- DOI: 10.1002/cncr.32834
Primary dural lymphomas: Clinical presentation, management, and outcome
Abstract
Background: Clinical experience is limited for primary central nervous system (CNS) lymphoma that arises from the dura mater, which is denoted with the term primary dural lymphoma (PDL). This study was aimed at determining the relative incidence, presentation, and outcomes of PDL.
Methods: The institutional databases of the Divisions of Neuro-Oncology at the Massachusetts General Hospital and the Yale School of Medicine were retrospectively searched for patients with primary CNS lymphoma. Patients with pathologically confirmed dural lymphoma and no evidence of primary cerebral or systemic involvement were identified. Clinical data, diagnostic findings, treatments, and outcomes were recorded.
Results: A total of 20 patients with PDL were identified, and they represented 6.3% of the individuals with primary CNS lymphomas (20 of 316). Histopathological examination of PDL revealed the following underlying subtypes: diffuse large B-cell lymphoma (10 of 20 patients), marginal zone lymphoma (6 of 20), follicular lymphoma (2 of 20), undefined B-cell non-Hodgkin lymphoma (1 of 20), and T-cell non-Hodgkin lymphoma (1 of 20). On imaging, all tumors appeared as extra-axial masses with avid contrast enhancement and mostly mimicked meningioma. The median apparent diffusion coefficient value was 667 ± 26 mm2 /s. Cerebrospinal fluid analyses and symptoms were nonspecific, and the diagnosis rested on tissue analysis. Therapeutic approaches included surgery, radiotherapy, and chemotherapy. The median overall survival was not reached after 5 years. Three patients were deceased at database closure because of tumor progression. The extent of tumor resection correlated positively with overall survival (P = .044).
Conclusions: PDL is a rare variant of primary CNS lymphoma that can be radiographically mistaken for meningioma. The outcome is excellent with multimodality treatment, and aggressive surgery may convey a survival advantage in select cases.
Keywords: central nervous system; imaging; lymphoma; primary dural lymphoma; therapy.
© 2020 American Cancer Society.
Similar articles
-
Primary lymphoblastic B-cell lymphoma of the cranial dura mater: a case report and review of the literature.Leuk Lymphoma. 2005 Nov;46(11):1651-7. doi: 10.1080/10428190500215126. Leuk Lymphoma. 2005. PMID: 16334908
-
Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.Leuk Lymphoma. 2017 Apr;58(4):882-888. doi: 10.1080/10428194.2016.1218006. Epub 2016 Sep 21. Leuk Lymphoma. 2017. PMID: 27649904 Free PMC article.
-
Primary central nervous system lymphoma: A curable disease.Hematol Oncol. 2019 Jun;37 Suppl 1:15-18. doi: 10.1002/hon.2598. Hematol Oncol. 2019. PMID: 31187523 Review.
-
[Therapeutic management of central nervous system lymphomas in a single hematological institute].Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Orv Hetil. 2009. PMID: 19812012 Hungarian.
-
Primary dural lymphomas: a review.Neurosurg Focus. 2006 Nov 15;21(5):E5. doi: 10.3171/foc.2006.21.5.6. Neurosurg Focus. 2006. PMID: 17134121 Review.
Cited by
-
Involved-Site Radiation Therapy Enables Effective Disease Control in Parenchymal Low-Grade Primary Cerebral Lymphoma.Cancers (Basel). 2023 Nov 24;15(23):5564. doi: 10.3390/cancers15235564. Cancers (Basel). 2023. PMID: 38067268 Free PMC article.
-
Spinal Meningeal Mass Lesion: A Rare Presentation of Primary Dural Follicular Lymphoma.Neurologist. 2024 Mar 1;29(2):122-125. doi: 10.1097/NRL.0000000000000535. Neurologist. 2024. PMID: 37839092 Free PMC article.
-
Freiburg Neuropathology Case Conference : A 58-year-old Patient Presenting with Dizziness, Nausea and Diplopia 12 Months after Total Resection of a Left-sided Temporal Glioblastoma Multiforme.Clin Neuroradiol. 2022 Dec;32(4):1141-1148. doi: 10.1007/s00062-022-01224-4. Epub 2022 Nov 21. Clin Neuroradiol. 2022. PMID: 36414742 Free PMC article. No abstract available.
-
The great mimicker of dural pathology: primary dural diffuse large B-cell lymphoma.Wien Klin Wochenschr. 2023 Sep;135(17-18):496-498. doi: 10.1007/s00508-023-02190-8. Epub 2023 Apr 17. Wien Klin Wochenschr. 2023. PMID: 37069406 No abstract available.
-
SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):709-717. doi: 10.1016/j.clml.2022.06.002. Epub 2022 Jun 6. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35787364 Free PMC article. Review.
References
-
- Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19:v1-v88.
-
- Iwamoto FM, DeAngelis LM, Abrey LE. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology. 2006;66:1763-1765.
-
- de la Fuente MI, Haggiagi A, Moul A, et al. Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leuk Lymphoma. 2017;58:882-888.
-
- Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16:e322-e332.
-
- Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical